Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Operating expenses:
Research and development	$ 12,757	$ 16,824
General and administrative	9,106	6,489
Total operating expenses	21,863	23,313
Loss from operations	(21,863)	(23,313)
Interest income	72	227
Other income	150	0
Net loss	(21,641)	(23,086)
Other comprehensive income:
Foreign currency translation adjustments	(114)	0
Unrealized loss on available for sale investments	(313)	(124)
Total comprehensive loss	$ (22,068)	$ (23,210)
Net loss per share - basic and diluted	$ (0.72)	$ (0.78)
Weighted average shares of common stock outstanding - basic and diluted	30,134,445	29,554,921